Factors influencing concomitant use of complementary and alternative medicines with warfarin

Journal of Pharmacy Practice and Research

Volumn 40, Issue 4, 2010, Pages 294-299

  Hasan, Shahzad S ^a   Feng, Siow R ^a   Ahmadi, Keivan ^a   Ahmad, Kamarunnesa M ^b   Chong, David W K ^b   Anwar, Mudassir ^a   Badarudin, Nurul Z ^b  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b Serdang Hospital   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA TOCOPHEROL; FISH OIL; GLUCOSAMINE; MINERAL; PANAX NOTOGINSENG EXTRACT; VITAMIN; WARFARIN;

ACUPUNCTURE; ADULT; ADVERSE OUTCOME; ALTERNATIVE MEDICINE; ANOREXIA; ANTICOAGULANT THERAPY; ARTICLE; CHINESE MEDICINE; CROSS-SECTIONAL STUDY; CRYOTHERAPY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FLATULENCE; GINGIVA BLEEDING; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HERBAL MEDICINE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MASSAGE; MYALGIA; SKIN BRUISING; STOMACH PAIN; TRADITIONAL MEDICINE;

EID: 78751551082     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2010.tb00563.x     Document Type: Article

References (40)

1. Jonas WB. Advising patients on the use of complementary and alternative medicine. Appl Psychophysiol Biofeedback 2001; 26: 205-14.
2. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997; 54: 692-3.
3. Cohen MH. Complementary and integrative medical therapies, the FDA, and the NIH: definitions and regulation. Dermatol Ther 2003; 16: 77-84.
4. Saw JT, Bahari MB, Ang HH, Lim YH. Potential drug-herb interaction with antiplatelet/anticoagulant drugs. Complement Ther Clin Pract 2006; 12: 236-41.
5. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies with warfarin. Am J Health Syst Pharm 2000; 57: 1221-30.
6. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-8.
7. Ramsay NA, Kenny MW, Davies G, Patel JP. Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 2005; 130: 777-80.
8. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133: 160S-198S.
9. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarinrelated bleeding events and supratherapeutic international normalized ratio associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 2007; 27: 1237-47.
10. Zuckerman IH, Steinberger EK, Ryder PT, Haines S. Herbal product use among anticoagulation clinic patients. Am J Health Syst Pharm 2002; 59: 379-80.
11. Wong RS, Cheng G, Chan TY. Use of herbal medicines by patients receiving warfarin. Drug Saf 2003; 26: 585-8.
12. Lim MK, Sadarangani P, Chan HL, Heng JY. Complementary and alternative medicine use in multiracial Singapore. Complement Ther Med 2005; 13: 16-24.
13. Hawks JH, Moyad MA. CAM: definition and classification overview. Urol Nurs 2003; 23: 221-3.
14. Shumay DM, Maskarinec G, Kakai H, Gotay CC; Cancer Research Center of Hawaii. Why some cancer patients choose complementary and alternative medicine instead of conventional treatment. J Fam Pract 2001; 50: 1067.
15. AARP and National Center for Complementary and Alternative Medicine. Complementary and alternative medicine. What people 50 and older are using and discussing with their physicians. Washington DC: AARP; 2007. Available from
16. Robinson A, McGrail MR. Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 2004; 12: 90-8.
17. Taylor DM, Walsham N, Taylor SE, Wong L. Potential interactions between prescription drugs and complementary and alternative medicine among patients in the emergency department. Pharmacotherapy 2006; 26: 634-40.
18. Leung VW, Shalansky SJ, Lo MK, Jadusingh EA.. Prevalence of use and the risk of adverse effects associated with complementary and alternative medicine in a cohort of patients receiving warfarin. Ann Pharmcother 2009; 43: 875-81.
19. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by U.S. adults: 1997-2002. Altern Ther Health Med 2005; 11: 42-9.
20. Ernst E. Prevalence of use of complementary and alternative medicine: a systemic review. Bull World Health Organ 2000; 78: 252-7.
21. Fisher P, Ward A. Complementary medicine in Europe. BMJ 1994; 309: 107-11.
22. Zollman C, Vicker A. ABC of complementary medicine-users and practitioners of complementary medicine. BMJ 1999; 319: 836-8.
23. National Center for Complementary and Alternative Medicine. The use of complementary and alternative medicine in the United States. Bethesda: National Center for Complementary and Alternative Medicine; 2008. Available from
24. Keith VM, Kronenfeld JJ, Rivers PA, Liang SY. Assessing the effects of race and ethnicity on use of complementary and alternative therapies in the USA. Ethn Health 2005; 10: 19-32.
25. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008; 12: 1-23.
26. Palinkas LA, Kabongo ML; San Diego Unified Practice Research in Family Medicine Network. The use of complementary and alternative medicine by primary care patients. J Fam Pract 2000, 49: 1121-30.
27. Nilsson M, Trehn G, Asplund K. Use of complementary and alternative medicine remedies in Sweden. A population-based longitudinal study within the northern Sweden MONICA project. J Intern Med 2001; 250: 225-33.
28. Yahaya AH, Hassali MA, Awaisu A, Shafie AA. Factors associated with warfarin therapy knowledge and anticoagulation control among patients attending a warfarin clinic in Malaysia. J Clin Diag Res 2009; 3: 1663-70.
29. Zhang YG, Zhang HG, Zhang GY, Fan JS, Li XH, Liu YH, et al. Panax notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action. Clin Exp Pharmacol Physiol 2008; 35: 1238-44.
30. Khoury R. Update on government matters. Adverse interaction between glucosamine and warfarin. J Aust Traditional Med Society 2008, 14: 239.
31. Dahmer S, Schiller RM. Glucosamine. Am Fam Physician 2008; 78: 471-6.
32. Scoot GN, Rozenfeld V, Crain JL. Interaction of warfarin with glucosamine- chondroitin. Am J Health Syst Pharm 2004; 61: 1186.
33. Holcomb SS. Common herb drug interactions: what you should know. Nurse Pract 2009; 34: 21-9.
34. Williamson EM. Drug interactions between herbal and prescription medicines. Drug Saf 2003; 26: 1075-92.
35. Barnes J, Anderson LA, Phillipson JD. Herbal interactions. Pharm J 2003; 270: 118-21.
36. Awang DV, Fugh-Berman A. Herbal interactions with cardiovascular drugs. J Cardiovasc Nurs 2002; 16: 64-70.
37. Schmidt LM. Herbal remedies: the other drugs your patients take. Home Healthc Nurse 2004; 22: 169-77.
38. Aggarwal A, Ades PA. Interaction of herbal remedies with prescription cardiovascular medications. Coron Artery Dis 2001; 12: 581-4.
39. Chagan L, Ioselovich A, Asherova L, Chen JW. Use of alternative pharmacotherapy in management of cardiovascular diseases. Am J Manag Care 2002; 8: 270-85.
40. NHSSB Prescribing Support Team. Drugs to watch with warfarin. Ballymena: Northern Health and Social Services Board; 2006. Available from